History | Cardiovascular disease: risk assessment and reduction, including lipid modification | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

Guidance published

Consultation comments and responses (PDF 2.44 MB)

Published:

14 December 2023
Supporting documentation Acknowledgements (PDF 195 KB)

Published:

14 December 2023
Committee member list (PDF 142 KB)

Published:

14 December 2023
Equality impact assessment Final (PDF 221 KB)

Published:

14 December 2023

Stakeholder list updated

Stakeholder list (PDF 52 KB)

Published:

13 December 2023

Declaration of interests

Register of interests (PDF 701 KB)

Published:

13 December 2023

Draft guidance consultation

Draft guidance consultation
Draft guideline (PDF 306 KB)

Published:

22 September 2023
Evidence review D - escalation of lipid modification therapy for secondary prevention (PDF 7.13 MB)

Published:

22 September 2023
Evidence review Codes list for lipids (Excel 834 KB)

Published:

22 September 2023
Evidence review Network meta-analysis for change in LDL-C and non-HDL-C (PDF 1.06 MB)

Published:

22 September 2023
Supporting documentation Methods chapter (PDF 503 KB)

Published:

22 September 2023
Economic report (PDF 3.72 MB)

Published:

22 September 2023
Comments form (MSWord 48 KB)

Published:

22 September 2023
Equality impact assessment - indicator (PDF 113 KB)

Published:

22 September 2023

Additional documents published

Statement Information Event slideset (PDF 339 KB)

Published:

28 April 2023
Statement Information Event Non-industry attendees (PDF 98 KB)

Published:

28 April 2023
Statement Information Event Industry attendees (PDF 78 KB)

Published:

28 April 2023

Statement

Statement

Additional documents published

Economic plan (PDF 103 KB)

Published:

09 February 2023
Review protocols (PDF 348 KB)

Published:

09 February 2023

Committee meetings

Committee meeting
Minutes 1 (PDF 209 KB)

Published:

24 March 2023
Minutes 2 (PDF 217 KB)

Published:

09 March 2023
Minutes 3 (PDF 238 KB)

Published:

30 March 2023
Minutes 4 (PDF 231 KB)

Published:

11 May 2023
Minutes 5 (PDF 229 KB)

Published:

31 July 2023
Minutes 6 (PDF 220 KB)

Published:

23 October 2023

Scope published

Final scope Amended scope (PDF 126 KB)

Published:

09 February 2023

Stakeholder workshop

Workshop notes - attendee list (PDF 125 KB)

Published:

24 November 2022
Workshop notes - discussions (PDF 376 KB)

Published:

24 November 2022
Workshop notes - notes (PDF 148 KB)

Published:

24 November 2022